- Home
- MKTW vs FBRX Comparison
MKTW vs FBRX Comparison
Compare MKTW & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- FBRX
- Stock Information
- Founded
- MKTW 1999
- FBRX N/A
- Country
- MKTW United States
- FBRX United States
- Employees
- MKTW N/A
- FBRX N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- MKTW Technology
- FBRX Health Care
- Exchange
- MKTW Nasdaq
- FBRX Nasdaq
- Market Cap
- MKTW 30.3M
- FBRX 35.3M
- IPO Year
- MKTW N/A
- FBRX N/A
- Fundamental
- Price
- MKTW $15.76
- FBRX $6.80
- Analyst Decision
- MKTW
- FBRX Strong Buy
- Analyst Count
- MKTW 0
- FBRX 3
- Target Price
- MKTW N/A
- FBRX $80.50
- AVG Volume (30 Days)
- MKTW 28.3K
- FBRX 26.6K
- Earning Date
- MKTW 05-08-2025
- FBRX 05-20-2025
- Dividend Yield
- MKTW 4.68%
- FBRX N/A
- EPS Growth
- MKTW 207.28
- FBRX N/A
- EPS
- MKTW 3.12
- FBRX N/A
- Revenue
- MKTW $383,217,000.00
- FBRX N/A
- Revenue This Year
- MKTW N/A
- FBRX N/A
- Revenue Next Year
- MKTW $0.42
- FBRX N/A
- P/E Ratio
- MKTW $5.06
- FBRX N/A
- Revenue Growth
- MKTW N/A
- FBRX N/A
- 52 Week Low
- MKTW $9.08
- FBRX $4.11
- 52 Week High
- MKTW $33.60
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- MKTW 68.74
- FBRX 50.51
- Support Level
- MKTW $13.01
- FBRX $6.20
- Resistance Level
- MKTW $16.12
- FBRX $6.91
- Average True Range (ATR)
- MKTW 0.90
- FBRX 0.61
- MACD
- MKTW 0.19
- FBRX 0.01
- Stochastic Oscillator
- MKTW 89.63
- FBRX 52.63
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).